WALTHAM, Mass., June 16, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced it will report interim results from the Phase 1 SPY002 healthy volunteer trials on Tuesday, June 17, 2025. Following the announcement, the Company will host a conference call ...

Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations. WALTHAM, Mass., May 28, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announ ...

Core Insights - Genmab A/S is a biotech innovator focusing on antibody engineering and has a strategy that includes direct commercialization of its products Tivdak and Epcoritamab, as well as monetizing through partnerships and licensing drugs like Darzalex and Kesimpta [1] Group 1 - The company retains its value through innovative antibody engineering [1] - Genmab's strategy involves both direct product sales and partnerships for drug monetization [1]

Core Insights - SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease (IBD) with a pharmacokinetic profile supporting a potential best-in-class status [1][3] - The company plans to initiate a Phase 2 trial in mid-2025, which will include SPY001 and other candidates, with initial data expected in 2026 [1][2] Group 1: SPY001 Development - SPY001 has shown a human half-life of approximately 80 days, which is more than three times that of vedolizumab, allowing for potential quarterly or biannual dosing [3][4] - Interim data from the Phase 1 trial indicates that SPY001 is well tolerated and maintains target engagement at expected Phase 2 trough concentrations [4] Group 2: Clinical Trials and Future Plans - The Phase 2 platform trial will test SPY001 as a monotherapy and in combination with other therapies for ulcerative colitis patients, expected to begin mid-2025 [2][3] - Initial monotherapy data from the Phase 2 trial is anticipated in 2026 [1] Group 3: Preclinical and Clinical Data - Preclinical studies indicate that combined inhibition of α4β7 integrin and TL1A cytokine is superior to either monotherapy in mouse models of colitis [4] - The pharmacodynamic data supports rapid and sustained saturation of α4β7 receptors with a single dose of SPY001 [1][4] Group 4: Company Overview - Spyre Therapeutics focuses on developing next-generation therapies for IBD and other immune-mediated diseases through advanced antibody engineering and therapeutic combinations [5] - The company's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 [5]